Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Biotechnol ; 18(3): 193-8, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11503514

ABSTRACT

A magainin derivative, designated MSI-344, was produced in Escherichia coli as fusion protein, by utilizing a truncated amidophsphoribosyltransferase of E. coli as a fusion partner. Bacterial cells transformed with the gene encoding the fusion protein were grown to a high cell density and induced with isopropyl-1-thio-b-D-galatoside (IPTG) to initiate product expression. The fusion protein was accumulated into cytoplasmic inclusion body and recombinant MSI-344 was released from the fusion partner by hydroxylamine treatment. Following cleavage of the fusion protein with hydroxylamine, the released MSI-344 was purified to homogeneity by cationic exchange chromatography. The final purity was at least 95% by reversed-phase high performance liquid chromatography (RP-HPLC). Purified recombinant MSI-344 was found to be indistinguishable from the synthetic peptide determined by amino acid sequences and antimicrobial activity assay.


Subject(s)
Anti-Infective Agents/isolation & purification , Oligopeptides/isolation & purification , Peptides/isolation & purification , Amino Acid Sequence , Anti-Bacterial Agents , Anti-Infective Agents/pharmacology , Bacillus subtilis/drug effects , Chromatography, High Pressure Liquid/methods , Escherichia coli/drug effects , Genetic Vectors , Hydrogen-Ion Concentration , Molecular Sequence Data , Oligopeptides/genetics , Oligopeptides/pharmacology , Peptides/genetics , Peptides/pharmacology , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/pharmacology , Saccharomyces cerevisiae/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...